News summary

[Beida Pharmaceutical: The application for marketing authorization of Tibexil Tartrate Capsules accepted] Securities Times e Company Newsblockchaingamesmakemoney, Beida Pharmaceutical (300558) announced on the evening of May 6 that recently, the company applied for BPI-16350 (Tibeciclib Tartrate Capsules)"This product is combined with fulvestrant, which is suitable for previously accepted drugs.blockchaingamesmakemoney...

Newsletter text

[Beida Pharmaceutical: The application for marketing authorization of Tabexil Tartrate Capsules was accepted] Securities Times e Company News, Beida Pharmaceutical (300558) announced on the evening of May 6 that recently, the company applied for BPI-16350 (Tybciclib Tartrate Capsules) The marketing authorization application for "This product is combined with fulvestrant and is suitable for the treatment of locally advanced or advanced patients with hormone receptor (HR) positive and human epidermal growth factor receptor 2 (HER2) negative who have progressed after previous endocrine therapy" has been accepted by the State Food and Drug Administration.

(: Congratulations